An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Sponsor
Hoffmann-La Roche
Study ID
NCT07200375
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Glofitamab — DRUG
    Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Study Details

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Key Dates

Start date
Sep 29, 2025
Status verified
Jun 2026
Primary completion
Sep 29, 2029
Completion
Sep 29, 2029

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Glofitamab treatment
    Participants will be enrolled into the study either prior to initiation of glofitamab therapy or within 90 days of starting glofitamab therapy.

Primary Outcome Measure

real-world Progression-Free Survival (rwPFS) [ Time Frame: Up to approximately 4 years ]

Central Contacts

  • Reference Study ID Number: ML45172 https://forpatients.roche.com/
    888-662-6728 (U.S. and Canada)
    [email protected]
  • Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Related Studies